Relief Therapeutics to Get European Patent for Investigational Drug RLF‐TD011

Seeking AlphaFeb 11 04:01 ET

Relief Therapeutics Completes Strategic Transition With Sale of GOLIKE Rights Ex-US

AccesswireJan 22 01:20 ET

Relief Therapeutics Provides Update on Potential Transaction With Renexxion

AccesswireDec 27, 2024 01:20 ET

Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations

AccesswireDec 13, 2024 17:25 ET

Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

AccesswireNov 11, 2024 01:20 ET

Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment

AccesswireOct 21, 2024 01:20 ET

Relief Gains as Experimental Therapy Performs on Par With BioMarin's Kuvan

Seeking AlphaOct 4, 2024 10:18 ET

Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024

AccesswireSep 18, 2024 01:20 ET

Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024

AccesswireSep 2, 2024 01:20 ET

Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update

AccesswireAug 30, 2024 01:25 ET

Relief Therapeutics Secures up to $11 Million From Royalty Sales

AccesswireAug 5, 2024 01:20 ET

6-K: Report of foreign private issuer (related to financial reporting)

SECJun 3, 2024 17:14 ET · Announcements

Relief Therapeutics Forms New Executive Leadership Team, Names New CFO

Seeking AlphaMay 8, 2024 03:35 ET

RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting

AccesswireMar 27, 2024 02:20 ET

Relief Therapeutics Enters Into Exclusive U.S. License and Supply Agreement With Eton Pharmaceuticals for PKU GOLIKE

AccesswireMar 22, 2024 02:20 ET

Relief Therapeutics Renews CHF 50 Million Share Subscription Facility

AccesswireFeb 28, 2024 01:00 ET

Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth

AccesswireDec 5, 2023 01:20 ET

Relief Therapeutics Announces CEO Transition

AccesswireNov 22, 2023 03:00 ET